Endotis Pharma Reports Successful Completion of Phase I Program with EP42675, a First in Class Synthetic Parenteral Anticoagulant

PARIS--(BUSINESS WIRE)--BIOCITECH PARK, Paris- Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis and oncology, announced that EP42675 has successfully completed its Phase I program.